Role of nitric oxide in gastric motor and sensory functions in healthy subjects

S D Kuiken, M Vergeer, S H Heisterkamp, G N J Tytgat, G E E Boeckxstaens

Background and aims: Impaired accommodation and hypersensitivity to distension of the proximal stomach are considered to be important factors in the pathogenesis of dyspeptic complaints. As fundus relaxing agents may be effective in the treatment of these symptoms, insight into the mediators involved in fundic accommodation and associated perceptual responses is important. Therefore, we studied the effect of nitric oxide (NO) synthase inhibition by N\textsuperscript{\text{-}}monomethyl-\textsuperscript{L}-arginine (\textit{l}-NMMA) on fundic tone, postprandial sensations, and gastric perception in healthy volunteers.

Subjects and methods: Eighteen healthy volunteers participated in a double blind, placebo controlled, randomised study. They underwent a gastric barostat study to evaluate the effect of \textit{l}-NMMA on meal and distension induced sensations and on fundic relaxation in response to oral meal intake, intraduodenal lipid, and glucagon administration.

Results: Compared with placebo, \textit{l}-NMMA decreased fundic volume after oral meal intake (438 (55) v 304 (67) ml; n=8; p<0.05) and during intraduodenal lipid infusion (384 (37) v 257 (43) ml; n=10; p<0.05) but not after glucagon injection (570 (62) v 540 (52) ml; n=4; p=0.4). In addition, basal fundic volume was significantly reduced by \textit{l}-NMMA. Scores for nausea and satiation were decreased by \textit{l}-NMMA after oral meal intake but not during intraduodenal lipid infusion. Perception scores to gastric distension were not altered by \textit{l}-NMMA.

Conclusions: NO is involved in maintaining basal fundic tone and in meal induced fundic relaxation in humans, but not in visceral perception.

Data illustrating a role for NO in human proximal gastric motility and perception are limited to in vitro studies\textsuperscript{17} or to in vivo studies investigating the effect of NO donors such as nitrates.\textsuperscript{18–22} However, to gain more insight into the role of endogenous NO, studies evaluating the effect of an NO synthase inhibitor are required. We previously demonstrated that the selective NO synthase inhibitor N\textsuperscript{\text{-}}monomethyl-L-arginine (\textit{l}-NMMA) dose dependently affects small intestinal and oesophageal motility, illustrating that this chemical is a useful tool to investigate the role of endogenous NO in humans.\textsuperscript{23} Therefore, in the present study, we investigated the effect of \textit{l}-NMMA in healthy volunteers on basal fundic volume and fundic relaxation. In addition, perception of fundic distension and meal induced sensations were assessed.

SUBJECTS AND METHODS

Subjects

Eighteen healthy male volunteers (mean age 24 years, range 19–30) were studied. All subjects were free of gastrointestinal symptoms, with no previous gastrointestinal surgery, and were not taking any medications. Subjects were studied after an overnight fast and were not allowed to smoke or drink alcohol for at least 24 hours before the study. All volunteers gave written informed consent to participate in the study which was approved by the medical ethics committee of the Academic Medical Centre, Amsterdam.

Methods

Gastric barostat

The barostat allows continuous recording of proximal gastric volume using an intragastric bag set at a fixed pressure level.

Abbreviations: NO, nitric oxide; \textit{l}-NMMA, N\textsuperscript{\text{-}}monomethyl-\textsuperscript{L}-arginine; MDP, minimal distending pressure; VAS, visual analogue scale.
In addition, gastric sensitivity can be assessed by distending the intragastric bag. Following anaesthesia of the throat (10% xylocaine spray), subjects swallowed a 1200 ml polyethylene bag, tightly wrapped on the distal end of a double lumen polyvinyl tube (Salem Sump tube, Sherwood Medical St Louis, USA; outer diameter 4 mm). The bag was unfolded by inflating it with 500 ml of air and was positioned in the proximal stomach by gently pulling the catheter back. The catheter was connected to an electronic barostat that automatically corrected for the compressibility of air (Medtronic Functional Diagnostics, Stockholm, Sweden). Recorded data were stored on a personal computer using commercially available software (Polygram for Windows, Medtronic Functional Diagnostics, Stockholm, Sweden).

**Intraduodenal infusion**

**Study I:** A polyurethane nasoduodenal feeding tube was placed for lipid infusion (Flocare, Châtel Medical Devices SA, Switzerland; length 125 cm, outer diameter 3.3 mm). The catheter, containing a guidewire in the central lumen, was positioned 30 cm beyond the pyloric region, under fluoroscopic control. The guidewire was then removed and the catheter was connected to a perfusion pump. Based on previous studies, a 10% lipid solution (Intralipid, Pharmacia and Upjohn, the Netherlands; energy load 1.1 kcal/ml) was infused at a rate of 1 ml/min.

**Sensation scores**

Sensations of bloating, nausea, pain, and satiation were assessed individually, using a 10 cm continuous visual analogue scale (VAS: 0 cm=no sensation, 10 cm=worst ever). Perception of sensations induced by feeding was scored just before and at five minute intervals after meal intake or following the start of intraduodenal infusion of lipid (study I and II, respectively). Sensations perceived during gastric distension (study II) were scored halfway through each distension step, both during fasting and during intraduodenal infusion of lipid.

**Drugs**

\(L-NMMA\) (N'-monomethyl-L-arginine monoacetate) was supplied by Alexis Corporation (Switzerland) and donated by a generous grant from the Janssen Research Foundation (Belgium). \(L-NMMA\) was dissolved in a sterile 0.9% NaCl solution to a concentration of 15 mg/ml. Equal volumes of the vehicle were used in the control studies. Glucagon (Glucagen; glucagon hydrochloride) was supplied by Novo Nordisk Pharma (the Netherlands).

**Experimental protocols**

Three study protocols were used (see fig 1). Of the 18 volunteers, three participated in studies I and II and three participated in studies II and III. Therefore, the total number of subjects studied was 10 for study I, 10 for study II, and four for study III. All studies were designed in a double blind placebo controlled manner, performed on two separate days at least three days apart. Study I was designed to investigate the effect of \(L-NMMA\) on fundic relaxation after oral intake of a liquid caloric meal. In addition, sensations evoked by the test meal were studied. In study II, subjects received lipids intraduodenally via a nasoduodenal feeding tube. We chose this approach (1) to bypass the possible effects of NO synthase inhibition on gastric emptying and (2) to create a situation of increased sensitivity to gastric distension, as described previously.25 The effects of \(L-NMMA\) on sensations induced by duodenal lipid and by gastric distension were studied before and during intraduodenal administration of lipids. In addition, we studied fasting fundic volume and fundic relaxation induced by intraduodenal lipid. Study III was designed to evaluate a possible postjunctional effect of \(L-NMMA\). Therefore, in study III, we evaluated the effect of \(L-NMMA\) on basal volume and fundic relaxation after glucagon administration, known to relax the proximal stomach, probably via a direct NO independent mechanism.

**Study I:** fundic accommodation and sensations after oral meal intake

In this study, both proximal stomach and antpyloroduodenal motility were recorded by combining a gastric barostat test with antpyloroduodenal manometry. However, for clarity, the manometry data are presented in a separate paper.25

Subjects reported to the laboratory at 7:45 am. The barostat bag was positioned in the proximal stomach as described above. An intravenous line was placed in the left arm for infusions over 15 minutes. \(L-NMMA\) was infused intravenously at a rate of 12 mg/kg over five minutes (bolus) followed by maintenance infusion of 6.7 mg/kg/h (fig 1). In the control studies, an equal volume of saline was infused at equal rates. Twenty minutes after the start of the infusion, 200 ml of a liquid test meal (Nutridrink, Nutricia Zoetermeer, the Netherlands; energy load 300 kcal) was consumed with the aid of a straw. Fundic volume was recorded over the following 60 minutes. Postprandial sensations were scored every five minutes.

**Study II:** fundic tone and sensations before and after intraduodenal lipid

Subjects reported to the laboratory at 7:45 am. After placement and positioning of the nasoduodenal catheter and the barostat bag, an intravenous line was placed and an equilibration period of 30 minutes was allowed. Thereafter, MDP was determined as described above. Operating pressure was...
set at MDP+2 mm Hg and baseline intragastric bag volume was recorded for 15 minutes. Intravenous administration of either L-NMMA (bolus of 12 mg/kg over five minutes, followed by maintenance infusion of 6.7 mg/kg/h) or placebo was then started (fig 1). Basal volume during the first 15 minutes of infusion was recorded, followed by a series of four isobaric distensions at 3, 6, 9, and 12 mm Hg above MDP, in random order. Each pressure step lasted 60 seconds, with 120 second intervals at the level of MDP. Perception scores were assessed at each pressure step. Again, operating pressure was set at MDP+2 mm Hg and continuous intraduodenal lipid infusion was started 30 minutes after the first distension series. Perceived meal related sensations were scored every five minutes during lipid infusion. A second series of four random isobaric distensions at MDP+3, 6, 9, and 12 mm Hg was performed 30 minutes later while continuously infusing lipids, and perception scores were assessed at each distension level. Heart rate and blood pressure were measured every 10 minutes.

Study III: glucagon induced fundic relaxation
Subjects reported to the laboratory at 8:00 am. Placement of the barostat bag, equilibration, determination of MDP, and baseline volume recording (15 minutes) were performed as described above. The same dose of L-NMMA was used as in the previous two studies. Similar to study II, fasting fundic volume was recorded for 55 minutes (fig 1). At t=55 minutes, subjects received 1 mg of glucagon intravenously, flushed with 5 ml of saline, in the right forearm. Heart rate and blood pressure were measured every 10 minutes.

Data analysis

Fundic volume

Study I
Basal volume 15 minutes before and 20 minutes after the start of infusion (L-NMMA or placebo) was determined as mean volume over the given period. Meal induced relaxation was expressed as mean volume over the 60 minutes after the meal. Volume change (or ΔV) was determined as the difference between mean basal volume (before infusion) and mean postprandial volume. Based on previous studies, a volume change of >64 ml was considered normal.1

Study II
Basal volume was measured 15 minutes before and 15 minutes after the start of intraduodenal lipid infusion. Lipid induced relaxation was expressed as mean volume over 30 minutes after the meal. Mean fundic volume was similar before the start of placebo and L-NMMA (fig 2A). L-NMMA did not significantly alter basal volume 20 minutes after the start of infusion (fig 2A). In eight

Effect of L-NMMA on blood pressure and heart rate
All subjects tolerated the studies well. In study I, mean diastolic blood pressure was significantly increased from 73 (2) mm Hg after placebo to 84 (2) mm Hg after L-NMMA infusion (p<0.01) whereas mean heart rate was significantly decreased from 69 (5) bpm (placebo) to 58 (3) bpm (L-NMMA) (p<0.01). In study II, diastolic blood pressure increased from 75 (1) mm Hg (placebo) to 82 (2) mm Hg (L-NMMA) (p<0.01) and heart rate decreased from 60 (2) bpm (placebo) to 54 (2) bpm (L-NMMA) (p<0.01). In study III, L-NMMA increased diastolic blood pressure from 69 (3) mm Hg (placebo) to 79 (4) mm Hg (p<0.05) and heart rate decreased from 58 (4) bpm (placebo) to 52 (3) bpm (p<0.05). Systolic blood pressure was not significantly altered by L-NMMA. Cardiovascular effects were sustained during the course of the studies. No side effects were reported.

Effect of L-NMMA on basal fundic volume and fundic relaxation
Basal fundic volume and fundic relaxation induced by oral meal intake (study I)
Mean fundic volume was similar before the start of placebo and L-NMMA (fig 2A). L-NMMA did not significantly alter basal volume 20 minutes after the start of infusion (fig 2A). In eight
L-NMMA was comparable for both groups (fig 2C). Similar to study II, l-NMMA did not significantly alter fasting volume during the first 15 minutes but significantly decreased mean fasting fundic volume over the last 15 minutes of the recording time, 40–55 minutes following the start of drug infusion (fig 2C). Glucagon administration induced an instant and marked relaxation of the fundus in all (n=4) subjects which was not altered by l-NMMA (ΔV: 397 (71) ml and 356 (66) ml for placebo and l-NMMA, respectively; p=0.2). In addition, mean volume after glucagon was not significantly altered by l-NMMA compared with placebo (fig 2C).

**Effect of l-NMMA on visceral perception**

**Sensations after oral meal intake [study I]**

At baseline, subjects reported comparable sensation scores (see fig 3, t=0). Following the meal, subjects reported increased sensations of bloating, satiation, pain, and nausea. Scores for bloating and pain were not altered by l-NMMA whereas subjects reported significantly decreased scores for nausea and satiation during l-NMMA infusion compared with placebo (fig 3).

**Sensations after duodenal lipid infusion [study II]**

Sensation scores were comparable before the start of intraduodenal lipid administration. No significant scores for nausea and pain were reported during intraduodenal administration of lipid, during both placebo and l-NMMA administration (maximum score for nausea: 0.6 (0.4) and 0.4 (0.3) cm, respectively; maximum score for pain: 0.3 (0.2) and 0.3 (0.1) cm, respectively). Although sensation scores for bloating and satiation tended to increase slightly during intraduodenal lipid, subjects perceived only very low scores, during both placebo and l-NMMA (maximum score for bloating: 1.4 (0.5) and 1.6 (0.7) cm, respectively; maximum score for satiation: 1.4 (0.6) and 1.4 (0.6) cm, respectively). l-NMMA did not significantly alter any of the sensation scores compared with placebo.

**Sensation induced by gastric distension [study II]**

Subjects reported only mild sensations of pain and nausea during fundic distension while fasting. As shown in fig 4, intraduodenal lipid tended to increase the perception of pain and nausea, although this did not reach statistical difference. Scores for bloating and satiation were more pronounced in both distension series and significantly increased during intraduodenal lipid compared with placebo (fig 4). No significant effect on sensation scores during distension was seen between l-NMMA and control studies during both fasting and intraduodenal lipid infusion (fig 4).

**Effect of l-NMMA on fundic compliance**

Fundic compliance during fasting was not significantly altered (placebo 50 (4) v l-NMMA 46 (6) ml/mm Hg). Likewise, during infusion of lipid, mean fundic compliance was not significantly affected by l-NMMA (placebo 46 (3) v l-NMMA 50 (5) ml/mm Hg). Pressure-volume curves are shown in fig 5.

**DISCUSSION**

In this study, we evaluated the effect of NO synthase inhibition by l-NMMA on proximal gastric volume and perception in healthy human subjects. We showed that l-NMMA decreased basal fundic volume and reduced fundic relaxation both after ingestion of a liquid meal and during intraduodenal lipid infusion, indicating that NO is involved in modulating fundic tone. Finally, no effect of l-NMMA on perception was seen, indicating that, at least in healthy volunteers, NO has no major role in visceral perception.
Animal studies have provided abundant evidence that both basal tone and relaxation of the proximal stomach, induced by vagal stimulation, meal ingestion, or intraduodenal lipid, are mediated by NO. Similarly, we showed that NO synthesis inhibition by L-NMMA contracted the gastric fundus, resulting in a reduction in basal fundic volume. The effect was only observed after prolonged infusion of L-NMMA, most likely due to the time-dependent inhibitory effect of L-NMMA on NO synthase activity. In addition, L-NMMA reduced fundic volume following ingestion of a nutrient liquid meal and during intraduodenal lipid. It should be emphasised that the reduction in postprandial volume observed during L-NMMA may simply reflect functional antagonism, resulting from the contractile effect of L-NMMA on basal tone. However, fundic relaxation induced by glucagon, known to act by a direct and NO independent mechanism, was not affected by L-NMMA. Therefore, we concluded that the reduction in postprandial volume by L-NMMA resulted from an effect on NO release, illustrating that NO is involved in meal induced relaxation of the human proximal stomach. These findings are in line with the recent in vitro study by Tonini et al demonstrating that relaxation of muscle strips of the human proximal stomach induced by nerve stimulation is inhibited by NO synthase inhibition.

With respect to the site of action, L-NMMA may act at all possible levels as NO is found to act throughout the central nervous system and the enteric nervous system. The fact that fundic relaxation induced by glucagon was not inhibited by L-NMMA excludes a possible postjunctional effect on the fundic smooth muscle. In addition, we did not observe an effect of NO synthase inhibition on plasma pancreatic polypeptide concentrations, indicating that vagal efferent output was not altered by L-NMMA. Finally, no significant effect on reaction time was noted (data not shown), suggesting no sedative effect of L-NMMA. Thus although a central action of L-NMMA cannot be excluded under the current experimental conditions, these findings suggest that L-NMMA increases fundic tone by reducing nitroergic neuronal input at a peripheral level.
Impaired accommodation to a meal, as encountered in a number of clinical conditions, is considered an important pathophysiological mechanism responsible for dyspeptic complaints. For example, in functional dyspepsia, impaired accommodation is associated with early satiety and weight loss. 

Therefore, we anticipated that reduction in gastric relaxation by L-NMMA should increase postprandial sensation scores. In contrast, scores for nausea and satiety were significantly decreased. As NO is also involved in the modulation of visceral sensation, this effect could result from interaction of L-NMMA with perception. However, no changes in perception of gastric distension were reported during fasting. Furthermore, when the stomach was distended during intra gastric infusion of lipid, which is known to cause increased sensitivity in healthy subjects, no effect of L-NMMA was observed, excluding interference with visceral perception.

The observation that during L-NMMA infusion subjects only reported decreased sensation scores after oral meal intake may therefore result from an effect of L-NMMA on gastric emptying. Alternatively, as gastric wall tension seems increased dyspeptic symptoms. Nist dexloxiglumide was associated with reduced rather than dyspepsia. Similar conclusions were drawn from a recent study. In human transient lower esophageal sphincter relaxations and fundus strip relaxations. Upon stimulation of nonadrenergic noncholinergic nerves in the rat gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol 1999;276:G373–7.

In contrast with several animal studies, we did not observe an effect of L-NMMA on visceral perception. This may be explained by the knowledge that NO has been shown to be mainly involved in the perception of visceral pain. The healthy volunteers in our study predominantly reported bloating and satiation on gastric distension, rather than pain. One might however anticipate that NO synthase inhibition may have an effect on perception in diabetic patients with visceral hypersensitivity. Animal models of visceral hyperalgesia indeed show upregulation of NO synthase producing neurones in the spinal cord. More importantly, NO synthase blockade normalised the hyperalgesic response but had no effect on perception in control animals. Therefore, L-NMMA may only affect visceral perception in the presence of hypersensitivity. Further studies investigating the effect of NO synthase inhibition in patients with functional dyspepsia are therefore warranted.

The use of NO donors in conditions characterised by impaired accommodation and/or hypersensitivity to gastric distension is controversial. Nitrates are known to induce gastric relaxation and earlier studies showed some relief of symptoms in functional dyspepsia but not in diabetes. Moreover, significant side effects, in particular headaches, are associated with the use of nitrates. Therefore, development of fundus relaxing drugs may need to be aimed at selectively activating NO producing neurones at the level of the myenteric plexus. For example, the 5-HT, agonist sumatriptan has been shown to relax the proximal stomach by activating NO producing neurones. Reduction of gastric tone by sumatriptan allowed higher gastric distension volumes in healthy volunteers before the threshold of discomfort was reached, and increased the amount of calories inducing maximum satiety in functional dyspepsia. 

Although these studies are promising, confirmation in larger clinical studies is awaited.

In summary, we showed that NO is involved in basal fundic tone and fundic relaxation in healthy volunteers but not in gastric perception. Reduction of meal induced relaxation did not result in increased perception of postprandial sensations. As NO inhibition did not affect gastric perception to distension and had no effect on sensations scored during intraduodenal lipid, the reduced scores for nausea and satiation by L-NMMA after oral meal intake are most likely caused by delayed gastric emptying.

ACKNOWLEDGEMENTS

SDK is supported by a grant from the Netherlands Digestive Diseases Foundation (MLDS), grant number 9S 99-38. Parts of the study have been published previously in abstract form.

References

34 Meller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 1993;52:127–36.